Browse FDA-Registered Products
Click here to go back to the Medical Specialties List
Click here to use the FDA-Registered Medical Devices Search Form.
Click here to browse FDA Product Classifications Alphabetically.
Medical Specialty: Immunology
| |
Product Classification |
| 1 |
ALBUMIN, ANTIGEN, ANTISERUM, CONTROL |
| 2 |
ALBUMIN, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 3 |
ALPHA-1 MICROGLOBULIN, ANTIGEN, ANTISERUM, CONTROL |
| 4 |
ALPHA-1-ACID-GLYCOPROTEIN, ANTIGEN, ANTISERUM, CONTROL |
| 5 |
ALPHA-1-ANTICHYMOTRYPSIN, ANTIGEN, ANTISERUM, CONTROL |
| 6 |
ALPHA-1-ANTITRYPSIN, ANTIGEN, ANTISERUM, CONTROL |
| 7 |
ALPHA-1-B-GLYCOPROTEIN, ANTIGEN, ANTISERUM, CONTROL |
| 8 |
ALPHA-1-LIPOPROTEIN, ANTIGEN, ANTISERUM, CONTROL |
| 9 |
ALPHA-1-T-GLYCOPROTEIN, ANTIGEN, ANTISERUM, CONTROL |
| 10 |
ALPHA-2-GLYCOPROTEINS, ANTIGEN, ANTISERUM, CONTROL |
| 11 |
ALPHA-2-HS-GLYCOPROTEIN, ANTIGEN, ANTISERUM, CONTROL |
| 12 |
ALPHA-2-MACROGLOBULIN, ANTIGEN, ANTISERUM, CONTROL |
| 13 |
ALPHA-2-MACROGLOBULIN, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 14 |
ALPHA-GLOBULIN, ANTIGEN, ANTISERUM, CONTROL |
| 15 |
ANTIBODIES, ANTI-ACTIN, ANTI-SMOOTH MUSCLE |
| 16 |
ANTIBODIES, ANTI-CYCLIC CITRULLINATED PEPTIDE (CCP) |
| 17 |
ANTIBODIES, GLIADIN |
| 18 |
ANTIBODIES,SACCHAROMYCES CEREVISIAE (S.CEREVISIAE) |
| 19 |
ANTI-DNA ANTIBODY (ENZYME-LABELED), ANTIGEN, CONTROL |
| 20 |
ANTI-DNA ANTIBODY, ANTIGEN AND CONTROL |
| 21 |
ANTI-DNA INDIRECT IMMUNOFLUORESCENT SOLID PHASE |
| 22 |
ANTIGEN, CANCER 549 |
| 23 |
ANTIMITOCHONDRIAL ANTIBODY, INDIRECT IMMUNOFLUORESCENT, ANTIGEN, CONTROL |
| 24 |
ANTINUCLEAR ANTIBODY (ENZYME-LABELED), ANTIGEN, CONTROLS |
| 25 |
ANTINUCLEAR ANTIBODY, ANTIGEN, CONTROL |
| 26 |
ANTINUCLEAR ANTIBODY, INDIRECT IMMUNOFLUORESCENT, ANTIGEN, CONTROL |
| 27 |
ANTIPARIETAL ANTIBODY, INDIRECT IMMUNOFLUORESCENT, ANTIGEN, CONTROL |
| 28 |
ANTI-RIBOSOMAL P ANTIBODIES |
| 29 |
ANTI-RNP ANTIBODY, ANTIGEN AND CONTROL |
| 30 |
ANTI-SM ANTIBODY, ANTIGEN AND CONTROL |
| 31 |
ANTISMOOTH MUSCLE ANTIBODY, INDIRECT IMMUNOFLUORESCENT, ANTIGEN, CONTROL |
| 32 |
ANTI-SS-A 52 AUTOANTIBODIES |
| 33 |
ASSAY, GENOTYPE, HIV DRUG RESISTANCE, IN VITRO |
| 34 |
AUTOANTIBODIES, ACETYLCHOLINE RECEPTOR, ACETYLCHOLINE BLOCKING AND NON-BLOCKING |
| 35 |
AUTOANTIBODIES, ANTI-RIBONUCLEIC ACID POLYMERASE (RNAP) III ANTIBODY |
| 36 |
AUTOANTIBODIES, ANTI-SOLUBLE LIVER ANTIGEN (SLA), AUTOIMMUNE HEPATITIS |
| 37 |
AUTOANTIBODIES, ENDOMYSIAL(TISSUE TRANSGLUTAMINASE) |
| 38 |
AUTOANTIBODIES, GLUTAMIC ACID DECARBOXYLASE (GAD) |
| 39 |
AUTOANTIBODIES, NUCLEAR BODY PROTEIN, SP100 |
| 40 |
AUTOANTIBODIES, NUCLEAR PORE GLYCOPROTEIN GP210 |
| 41 |
AUTOANTIBODIES,LKM-1(LIVER/KIDNEY MICROSOME,TYPE 1) |
| 42 |
AUTOANTIBODIES,SKIN(DESMOGLEIN 1 AND DESMOGLEIN 3) |
| 43 |
BENCE-JONES PROTEIN, ANTIGEN, ANTISERUM, CONTROL |
| 44 |
BETA-2-GLYCOPROTEIN I, ANTIGEN, ANTISERUM, CONTROL |
| 45 |
BETA-GLOBULIN, ANTIGEN, ANTISERUM, CONTROL |
| 46 |
BIOSENSOR,IMMUNOASSAY,MYOGLOBIN |
| 47 |
CANCER MONITORING TEST SYSTEM, SOLUBLE MESOTHELIN-RELATED PEPTIDES, EPITHELIOID/BIPHASIC MESOTHELIOMA |
| 48 |
CARBONIC ANHYDRASE C, ANTIGEN, ANTISERUM, CONTROL |
| 49 |
CARDIAC C-REACTIVE PROTEIN, ANTIGEN, ANTISERUM, AND CONTROL |
| 50 |
CERULOPLASMIN, ANTIGEN, ANTISERUM, CONTROL |
| 51 |
CLASSIFIER, PROGNOSTIC, RECURRENCE RISK ASSESSMENT, RNA GENE EXPRESSION, BREAST CANCER |
| 52 |
COLOSTRUM, ANTIGEN, ANTISERUM, CONTROL |
| 53 |
COMPLEMENT C1 INHIBITOR (INACTIVATOR), ANTIGEN, ANTISERUM, CONTROL |
| 54 |
COMPLEMENT C1Q, ANTIGEN, ANTISERUM, CONTROL |
| 55 |
COMPLEMENT C1R, ANTIGEN, ANTISERUM, CONTROL |
| 56 |
COMPLEMENT C1S, ANTIGEN, ANTISERUM, CONTROL |
| 57 |
COMPLEMENT C3, ANTIGEN, ANTISERUM, CONTROL |
| 58 |
COMPLEMENT C3B ACTIVATOR IMMUNOASSAY REAGENTS |
| 59 |
COMPLEMENT C3B ACTIVATOR, ANTIGEN, ANTISERUM, CONTROL |
| 60 |
COMPLEMENT C4, ANTIGEN, ANTISERUM, CONTROL |
| 61 |
COMPLEMENT C5, ANTIGEN, ANTISERUM, CONTROL |
| 62 |
COMPLEMENT C9, ANTIGEN, ANTISERUM, CONTROL |
| 63 |
C-REACTIVE PROTEIN, ANTIGEN, ANTISERUM, AND CONTROL |
| 64 |
CYTOKERATINS |
| 65 |
DEVICES, MEASURE, ANTIBODIES TO GLOMERULAR BASEMENT MEMBRANE (GBM) |
| 66 |
ELECTROPHORESIS INSTRUMENTATION |
| 67 |
ENZYME IMMUNOASSAY, ANTIPARIETAL CELL ANTIBODY, ANTIGEN, CONTROL |
| 68 |
EQUIPMENT, ROCKET IMMUNOELECTROPHORESIS |
| 69 |
EXTRACTABLE ANTINUCLEAR ANTIBODY, ANTIGEN AND CONTROL |
| 70 |
FAB, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 71 |
FAB, RHODAMINE, ANTIGEN, ANTISERUM, CONTROL |
| 72 |
FACTOR B, ANTIGEN, ANTISERUM, CONTROL |
| 73 |
FACTOR XIII A, S, ANTIGEN, ANTISERUM, CONTROL |
| 74 |
FC, ANTIGEN, ANTISERUM, CONTROL |
| 75 |
FC, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 76 |
FC, RHODAMINE, ANTIGEN, ANTISERUM, CONTROL |
| 77 |
FERRITIN, ANTIGEN, ANTISERUM, CONTROL |
| 78 |
FIBRINOPEPTIDE A, ANTIGEN, ANTISERUM, CONTROL |
| 79 |
FLUOROMETER |
| 80 |
FRACTION V, ANTIGEN, ANTISERUM, CONTROL |
| 81 |
GAMMA GLOBULIN, ANTIGEN, ANTISERUM, CONTROL |
| 82 |
GAMMA GLOBULIN, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 83 |
HAPTOGLOBIN, ANTIGEN, ANTISERUM, CONTROL |
| 84 |
HEMOPEXIN, ANTIGEN, ANTISERUM, CONTROL |
| 85 |
IGA, ANTIGEN, ANTISERUM, CONTROL |
| 86 |
IGA, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 87 |
IGA, PEROXIDASE, ANTIGEN, ANTISERUM, CONTROL |
| 88 |
IGD, ANTIGEN, ANTISERUM, CONTROL |
| 89 |
IGD, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 90 |
IGD, PEROXIDASE, ANTIGEN, ANTISERUM, CONTROL |
| 91 |
IGE, ANTIGEN, ANTISERUM, CONTROL |
| 92 |
IGE, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 93 |
IGE, PEROXIDASE, ANTIGEN, ANTISERUM, CONTROL |
| 94 |
IGG (FAB FRAGMENT SPECIFIC), ANTIGEN, ANTISERUM, CONTROL |
| 95 |
IGG (FC FRAGMENT SPECIFIC), ANTIGEN, ANTISERUM, CONTROL |
| 96 |
IGG (GAMMA CHAIN SPECIFIC), ANTIGEN, ANTISERUM, CONTROL |
| 97 |
IGG, ANTIGEN, ANTISERUM, CONTROL |
| 98 |
IGG, FERRITIN, ANTIGEN, ANTISERUM, CONTROL |
| 99 |
IGG, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 100 |
IGG, PEROXIDASE, ANTIGEN, ANTISERUM, CONTROL |
| 101 |
IGM (MU CHAIN SPECIFIC), ANTIGEN, ANTISERUM, CONTROL |
| 102 |
IGM, ANTIGEN, ANTISERUM, CONTROL |
| 103 |
IGM, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 104 |
IGM, PEROXIDASE, ANTIGEN, ANTISERUM, CONTROL |
| 105 |
IGM, RHODAMINE, ANTIGEN, ANTISERUM, CONTROL |
| 106 |
IMMUNOCHEMICAL, CERULOPLASMIN |
| 107 |
IMMUNOCHEMICAL, THYROGLOBULIN AUTOANTIBODY |
| 108 |
IMMUNOCHEMICAL, TRANSFERRIN |
| 109 |
IMMUNOELECTROPHORETIC, IMMUNOGLOBULINS, (G, A, M) |
| 110 |
INDIRECT COPPER ASSAY, CERULOPLASMIN |
| 111 |
INTER-ALPHA TRYPSIN INHIBITOR, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 112 |
KAPPA, ANTIGEN, ANTISERUM, CONTROL |
| 113 |
KAPPA, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 114 |
KAPPA, PEROXIDASE, ANTIGEN, ANTISERUM, CONTROL |
| 115 |
KIT, RIA, ANTIGEN & KIT, PROSTATIC ACID PHOSPHATASE |
| 116 |
KIT, RIA, MYELIN BASIC PROTEIN |
| 117 |
KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS |
| 118 |
KIT, TEST,ALPHA-FETOPROTEIN FOR TESTICULAR CANCER |
| 119 |
KIT,TEST(DONORS),FOR BLOODBORNE PATHOGEN |
| 120 |
LACTOFERRIN, ANTIGEN, ANTISERUM, CONTROL |
| 121 |
LAMBDA, ANTIGEN, ANTISERUM, CONTROL |
| 122 |
LAMBDA, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 123 |
LIPOPROTEIN X, ANTIGEN, ANTISERUM, CONTROL |
| 124 |
LIPOPROTEIN, LOW-DENSITY, ANTIGEN, ANTISERUM, CONTROL |
| 125 |
METHOD, IMMUNODIFFUSION, IMMUNOGLOBULINS (G, A, M) |
| 126 |
METHOD, NEPHELOMETRIC, IMMUNOGLOBULINS (G, A, M) |
| 127 |
MULTIPLE AUTOANTIBODIES, INDIRECT IMMUNOFLUORESCENT, ANTIGEN, CONTROL |
| 128 |
MYOGLOBIN, ANTIGEN, ANTISERUM, CONTROL |
| 129 |
MYOGLOBIN, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 130 |
NEPHELOMETER |
| 131 |
NG1M(A), ANTIGEN, ANTISERUM, CONTROL |
| 132 |
NG3M(BO), ANTIGEN, ANTISERUM, CONTROL |
| 133 |
NG4M(A), ANTIGEN, ANTISERUM, CONTROL |
| 134 |
PLASMINOGEN, ANTIGEN, ANTISERUM, CONTROL |
| 135 |
PLATES AND EQUIPMENT, RADIAL IMMUNODIFFUSION |
| 136 |
PLATES, OUCHTERLONY AGAR |
| 137 |
P-PHENYL-ENEDIAMINE/EDTA (SPECTROPHOTOMETRIC), CERULOPLASMIN |
| 138 |
PREALBUMIN, ANTIGEN, ANTISERUM, CONTROL |
| 139 |
PREALBUMIN, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 140 |
PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS |
| 141 |
PROTEIN, COMPLEMENT, ANTIGEN, ANTISERUM, CONTROL |
| 142 |
PROTEINS, BETA AMYLOID AND PRECURSOR |
| 143 |
PROTHROMBIN, ANTIGEN, ANTISERUM, CONTROL |
| 144 |
QUALITY CONTROL MATERIAL, GENETICS, DNA |
| 145 |
RADIOIMMUNOASSAY (TWO-SITE SOLID PHASE), FERRITIN |
| 146 |
RADIOIMMUNOASSAY FOR PROSTATE-SPECIFIC ANTIGEN |
| 147 |
RADIOIMMUNOASSAY, IMMUNOGLOBULINS (D, E) |
| 148 |
RADIOIMMUNOASSAY, IMMUNOGLOBULINS (G, A, M) |
| 149 |
REAGENT, COMPLEMENT |
| 150 |
REAGENT, IMMUNOASSAY, IGG |
| 151 |
RETINOL-BINDING PROTEIN, ANTIGEN, ANTISERUM, CONTROL |
| 152 |
SEMINAL FLUID, ANTIGEN, ANTISERUM, CONTROL |
| 153 |
SPERM, ANTIGEN, ANTISERUM, CONTROL |
| 154 |
SUPPORT GELS |
| 155 |
SYSTEM, AUTOMATED SCANNING MICROSCOPE AND IMAGE ANALYSIS FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ASSAYS |
| 156 |
SYSTEM, BLOOD COLLECTION, RNA STABILIZATION, RNA PURIFICATION, RT-PCR MOLECULAR DIAGNOSTIC TEST |
| 157 |
SYSTEM, CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, GENE MUTATION DETECTION |
| 158 |
SYSTEM, TEST, ALPHA-FETOPROTEIN, RIA |
| 159 |
SYSTEM, TEST, ANTICARDIOLIPIN IMMUNOLOGICAL |
| 160 |
SYSTEM, TEST, BETA-2-MICROGLOBULIN IMMUNOLOGICAL |
| 161 |
SYSTEM, TEST, CARBOHYDRATE ANTIGEN (CA19-9), FOR MONITORING AND MANAGEMENT OF PANCREATIC CANCER |
| 162 |
SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN |
| 163 |
SYSTEM, TEST, C-REACTIVE PROTEIN |
| 164 |
SYSTEM, TEST, HER-2/NEU, MONITORING |
| 165 |
SYSTEM, TEST, HER-2/NEU, NUCLEIC ACID OR SERUM |
| 166 |
SYSTEM, TEST, HYPERSENSITIVITY PNEUMONITIS |
| 167 |
SYSTEM, TEST, IMMUNOLOGICAL, ANTIGEN, TUMOR |
| 168 |
SYSTEM, TEST, INFECTIOUS MONONUCLEOSIS |
| 169 |
SYSTEM, TEST, RADIOALLERGOSORBENT (RAST) IMMUNOLOGICAL |
| 170 |
SYSTEM, TEST, RHEUMATOID FACTOR |
| 171 |
SYSTEM, TEST, SYSTEMIC LUPUS ERYTHEMATOSUS |
| 172 |
SYSTEM, TEST, THYROID AUTOANTIBODY |
| 173 |
SYSTEM, TEST, TUMOR MARKER, MONITORING, BLADDER |
| 174 |
SYSTEM,DETECTION,BACTERIAL, FOR PLATELET TRANSFUSION PRODUCTS |
| 175 |
SYSTEM,TEST,ANTIBODIES,B2 - GLYCOPROTEIN I (B2 - GPI) |
| 176 |
SYSTEM,TEST,THYROGLOBULIN |
| 177 |
SYSTEM,TEST,TUMOR MARKER,FOR DETECTION OF BLADDER CANCER |
| 178 |
TEST SYSTEM, ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) |
| 179 |
TEST, ALPHA FETOPROTEIN L3 SUBFRACTION (AFP-L3%), FOR HEPATOCELLULAR CARCINOMA RISK ASSESSMENT |
| 180 |
TEST, CARBOHYDRATE ANTIGEN (CA19-9) |
| 181 |
TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125) |
| 182 |
TEST, HIV DETECTION |
| 183 |
TEST, ISLET CELL ANTIBODY (ICA) |
| 184 |
TEST, MYELIN BASIC PROTEIN |
| 185 |
TEST, SYSTEM, IMMUNOASSAY, LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 |
| 186 |
TEST, TUMOR-ASSOCIATED ANTIGEN, TENNAGEN |
| 187 |
TEST,DONOR,CMV |
| 188 |
TEST,DONOR,SYPHILIS,ANTIGENS,TREPONEMAL |
| 189 |
TEST,EQUIPMENT,AUTOMATED BLOODBORNE PATHOGEN |
| 190 |
TEST,PROSTATE SPECIFIC ANTIGEN,FREE,(NONCOMPLEXED) TO DISTINGUISH PROSTATE CANCER FROM BENIGN CONDITIONS |
| 191 |
THYROGLOBULIN, ANTIGEN, ANTISERUM, CONTROL |
| 192 |
THYROGLOBULIN, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 193 |
TOTAL SPINAL-FLUID, ANTIGEN, ANTISERUM, CONTROL |
| 194 |
TOTAL,PROSTATE SPECIFIC ANTIGEN(NONCOMPLEXED&COMPLEXED) FOR DETECTION OF PROSTATE CANCER |
| 195 |
TRANSFERRIN, ANTIGEN, ANTISERUM, CONTROL |
| 196 |
TRANSFERRIN, FITC, ANTIGEN, ANTISERUM, CONTROL |
| 197 |
TRANSFERRIN, RHODAMINE, ANTIGEN, ANTISERUM, CONTROL |
| 198 |
WHOLE BLOOD PLASMA, ANTIGEN, ANTISERUM, CONTROL |
| 199 |
WHOLE HUMAN SERUM, ANTIGEN, ANTISERUM, CONTROL |
|
|
|
|
